Aperio Group LLC grew its stake in Dr.Reddy's Laboratories Ltd (NYSE:RDY) by 1.5% during the fourth quarter, HoldingsChannel reports. The firm owned 184,726 shares of the company’s stock after buying an additional 2,752 shares during the quarter. Aperio Group LLC’s holdings in Dr.Reddy's Laboratories were worth $6,938,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of RDY. Bank of New York Mellon Corp boosted its stake in shares of Dr.Reddy's Laboratories by 283.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 28,255 shares of the company’s stock valued at $1,191,000 after purchasing an additional 20,878 shares in the last quarter. Alliancebernstein L.P. raised its holdings in Dr.Reddy's Laboratories by 16.4% in the 2nd quarter. Alliancebernstein L.P. now owns 9,085 shares of the company’s stock valued at $383,000 after buying an additional 1,277 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Dr.Reddy's Laboratories by 11.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 10,087 shares of the company’s stock valued at $426,000 after buying an additional 1,054 shares during the last quarter. Northern Trust Corp raised its holdings in Dr.Reddy's Laboratories by 2.7% in the 2nd quarter. Northern Trust Corp now owns 427,419 shares of the company’s stock valued at $18,012,000 after buying an additional 11,378 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its holdings in Dr.Reddy's Laboratories by 6.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 194,967 shares of the company’s stock valued at $8,216,000 after buying an additional 12,274 shares during the last quarter. Institutional investors own 13.97% of the company’s stock.

RDY has been the subject of a number of research reports. Jefferies Group dropped their price objective on shares of Dr.Reddy's Laboratories from $31.62 to $30.51 and set an “underperform” rating for the company in a report on Wednesday, November 1st. Zacks Investment Research upgraded shares of Dr.Reddy's Laboratories from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, ValuEngine lowered shares of Dr.Reddy's Laboratories from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $30.51.

Dr.Reddy's Laboratories Ltd (NYSE:RDY) opened at $34.11 on Monday. The stock has a market cap of $5,656.43, a P/E ratio of 36.68 and a beta of 0.23. Dr.Reddy's Laboratories Ltd has a fifty-two week low of $29.83 and a fifty-two week high of $45.00. The company has a quick ratio of 1.08, a current ratio of 1.50 and a debt-to-equity ratio of 0.20.

TRADEMARK VIOLATION WARNING: “Dr.Reddy's Laboratories Ltd (RDY) Shares Bought by Aperio Group LLC” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://theolympiareport.com/2018/02/12/dr-reddys-laboratories-ltd-rdy-shares-bought-by-aperio-group-llc.html.

About Dr.Reddy's Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr.Reddy's Laboratories Ltd (NYSE:RDY).

Institutional Ownership by Quarter for Dr.Reddy's Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.